Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + ezetimibe + acetylsalicylic acid
- Development stage
- Preclinical
- Lead developer
- Midas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvastatin + ezetimibe + acetylsalicylic acid is a fixed-dose combination (FDC) small molecule therapy in development by Midas Pharma for the management of dyslipidemia and the reduction of cardiovascular risk. The combination leverages three distinct mechanisms: atorvastatin, an HMG-CoA reductase inhibitor, reduces hepatic cholesterol synthesis; ezetimibe, a cholesterol absorption inhibitor, targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine; and acetylsalicylic acid (aspirin), a cyclooxygenase (COX) inhibitor, provides antiplatelet and anti-inflammatory benefits. By combining these agents into a single oral tablet, the product is intended to simplify complex treatment regimens for patients requiring intensive lipid-lowering therapy and secondary cardiovascular prevention.
- Other names
- atorvastatin + ezetimibe + ASAatorvastatin + ezetimibe + aspirin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PGHS-1 (Prostaglandin G/H Synthase 1)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on atorvastatin + ezetimibe + acetylsalicylic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + ezetimibe + acetylsalicylic acid.